| MDL | - |
|---|---|
| Molecular Weight | 534.36 |
| Molecular Formula | C21H14F8N6O2 |
| SMILES | FC1=C(C=CC=C1)CN2C(C3=NOC=C3)=CC(C4=NC=C(F)C(NCC(C(F)(F)F)(O)C(F)(F)F)=N4)=N2 |
Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase stimulator, enhances NO signaling, acts as a vasodilator. Praliciguat (IW-1973) stimulates sGC in HEK-293 cells with an EC 50 of 197 nM [1] .
EC50: 197 nM (sGC) [1]
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02616861 | Cyclerion Therapeutics |
Healthy
|
November 2015 | Phase 1 |
| NCT03091920 | Cyclerion Therapeutics |
Diabetes Mellitus, Type 2|Hypertension
|
February 28, 2017 | Phase 2 |
| NCT03217591 | Akebia Therapeutics|Cyclerion Therapeutics |
Type 2 Diabetes Mellitus With Diabetic Nephropathy
|
August 1, 2017 | Phase 2 |
| NCT03499106 | Cyclerion Therapeutics |
Healthy
|
April 12, 2018 | Phase 1 |
| NCT03254485 | Akebia Therapeutics|Cyclerion Therapeutics |
Heart Failure With Preserved Ejection Fraction
|
November 7, 2017 | Phase 2 |
| NCT02906579 | Cyclerion Therapeutics |
Diabetes Mellitus, Type 2|Hypertension
|
September 2016 | Phase 2 |
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : 250 mg/mL ( 467.85 mM ; Need ultrasonic)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.8714 mL | 9.3570 mL | 18.7140 mL |
| 5 mM | 0.3743 mL | 1.8714 mL | 3.7428 mL |
| 10 mM | 0.1871 mL | 0.9357 mL | 1.8714 mL |
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.89 mM); Clear solution